EDGE
Get a demo
Log In
All Updates

All Updates

icon
Filter
Earnings/results
Babylon Health releases Q1 2023 earnings; company announces plans to de-list
Telehealth
May 10, 2023
This week:
Funding
Turbine secures investment from Accenture Ventures
AI Drug Discovery
Yesterday
FDA approval
Karius Receives FDA breakthrough designation for its DNA-based blood test
Precision Medicine
May 16, 2024
Funding
Metabolon raises USD 60 million in debt financing to strengthen R&D capabilities and enhance metabolomics platform
Precision Medicine
May 16, 2024
Partnerships
Accelerated Biosciences and Spanios partner to advance therapeutic design in solid tumor cancers
Precision Medicine
May 16, 2024
Partnerships
Telo Genomics and Emery Pharma put together their technologies to provide clinical R&D solutions
Precision Medicine
May 16, 2024
Partnerships
Oxford Biodynamics partners with KCL to enhance rheumatoid arthritis treatment using EpiSwitch technology
Precision Medicine
May 16, 2024
Funding
Monte Rosa Therapeutics prices USD 100 million underwritten public funding
Precision Medicine
May 16, 2024
Partnerships
Nearby Computing and Alea partner to streamline mission-critical communication app deployment
Edge Computing
May 16, 2024
M&A
Snowflake reportedly in talks to acquire Reka AI for more than USD 1 billion to expand language model capabilities
Foundation Models
May 16, 2024
Funding
Stability AI to reportedly raise funds to settle debt
Foundation Models
May 16, 2024
May 10, 2023

Babylon Health releases Q1 2023 earnings; company announces plans to de-list

Earnings/results

  • Babylon released its earnings for Q1 2023, reporting a net loss per share of USD 2.53 compared to USD 1.71 the previous year. This performance beat analyst expectations of a net loss of USD 2.75. Overall, net losses increased to USD 62.2 million during the period compared to USD 29.1 million in the corresponding period of the previous year. 

  • Annual revenue grew 17% YoY to USD 311.1 billion. The company attributed the growth in revenue to organic growth in US value-based contract membership revenues, which grew 17% YoY to USD 287.5 million during Q1 2023. 

  • During Q1 2023, the company posted an adjusted EBITDA loss of USD 45.8 million (a 44.5% YoY reduction in losses) and adjusted EBITDA margins of -14.7% compared to -31.0% in the previous year. 

  • The company also announced that it has entered an amendment and restatement of its loan facility with AlbaCore Capital LLP and certain affiliates, securing up to an additional USD 34.5 million with similar terms to the original agreement. The facility was secured to support Babylon’s operations and help it take the company private in order to strengthen its operations. The company’s board has approved both the facility and the plan to take the company private, and as a result, withdraws its expectations for its FY2023 performance. The funding will be made available to Babylon in May and early June 2023, subject to the company meeting certain criteria.  

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.